Gapping up
In reaction to earnings/guidance:
- SJM +4%, MDT +2.8%, SXI +2.7%, HAIN +2.5%, BMO +1.1%, ATHM +1%
Other news:
- OVID +24.8% (Ovid Therapeutics and Takeda (TAK) announced positive topline results from the Phase 2 ELEKTRA study of soticlestat in children with Dravet syndrome or Lennox-Gastaut syndrome)
- MREO +9% (initiates Phase 1b/2 placebo-controlled clinical trial to evaluate the safety and efficacy of alvelestat in hospitalized, adult patients with moderate to severe COVID-19 respiratory disease)
- ALT +8.9% (announced additional results from the preclinical studies of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID)
- CAAS +8.2% (approved a share repurchase program of up to $5 million of its outstanding common shares periodically over the next 12 months)
- AMGN +4.2% (will join Dow 30 Index on Aug 31)
- HON +3.7% (will join Dow 30 Index on Aug 31)
- ALSN +3.3% (begins Vehicle Environmental Test services at Indianapolis facility)
- CRM +2.8% (will join Dow 30 Index on Aug 31)
- AGTC +1.9% (announced that preclinical data on transgene that is being evaluated in its Phase 1/2 clinical trial)
- STRO +1.5% (achieved a clinical supply milestone under its collaboration and license agreement with the healthcare division of Merck KGaA)
- PZZA +1.2% (preliminary estimated comparable sales information for the August fiscal period)
Analyst comments:
- GPS +5.3% (upgraded to Buy from Neutral at Citigroup)
- MERC +4% (upgraded to Sector Outperform from Neutral at CIBC)
- CROX +2.9% (upgraded to Buy from Neutral at B. Riley FBR)
- LB +2.6% (upgraded to Buy from Neutral at MKM Partners)
- ARGX +1.6% (initiated with an Outperform at Raymond James)
- SBUX +1.4% (upgraded to Buy from Hold at Stifel)
- XLRN +1.4% (initiated with a Strong Buy at Raymond James)
- ACAD +1.2% (initiated with an Outperform at Raymond James)
- NXPI +0.7% (initiated with an Overweight at Wells Fargo)
- NIO +0.5% (upgraded to Neutral from Sell at UBS)